Drugs / Colchicine
Colchicine
also known as
Colcrys · LoDoCo · (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol\[a\]heptalen-7-yl) acetamide · COLC · Colchcine · COLCHICINA LIRCA · Colchicine component of col-probenecid · Colchicine component of colbenemid · +16 more
Small molecule targets CYP1A2, NLRP3, TNF via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | GLOPERBA | — | 2024-08-28 | fda.gov ↗ |
| Approved | US (FDA) | COLBENEMID | — | 1961-07-27 | fda.gov ↗ |
Trials 175 · started per year
today
US approved 1961
1
1
1
1
3
6
9
4
5
2
1
7
10
3
2
4
4
5
20
18
15
8
17
14
14
1960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
Also used as a comparator or background therapy in 104 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07143136 Comparator | Aug 2025 → Mar 2026 overdue | myocardial infarction | Assiut University | Recruiting | No outcome recorded |
| Phase 0 | NCT06426537 Comparator | Oct 2022 → Mar 2023 | ST-elevation myocardial infarction | University of Brawijaya | Completed | No outcome recorded |
| Phase 0 | NCT05118737 Comparator | Oct 2021 → Apr 2022 | pneumonia | Hamad Medical Corporation | Unknown | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT06203977 Comparator | Nov 2024 → May 2026 overdue | chronic kidney disease, kidney failure | Hamilton Health Sciences Corporation | Recruiting | No outcome recorded |
| Phase 1 | NCT06304896 Comparator | May 2024 → May 2025 | chemotherapy-induced toxicity | Arab Contractors Medical Centre | Unknown | No outcome recorded |
| Phase 1 | NCT01160276 Comparator | May 2010 → Jan 2012 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06847204 Comparator | Feb → May 2025 | COVID-19 | Zaeema Kanwal | Completed | No outcome recorded |
| Phase 1/2 | NCT04790240 Comparator | Jan 2025 → Dec 2026 expected | COVID-19 | All Natural Medicine Clinic, LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05637398 Comparator | Dec 2022 → Sep 2025 | heart failure | I.M. Sechenov First Moscow State Medical University | Completed | No outcome recorded |
| Phase 1/2 | NCT04762771 Comparator | Dec 2020 → May 2021 | COVID-19 | Baptist Health South Florida | Terminated | No outcome recorded |
| Phase 233 trials | ||||||
| Phase 2 | NCT07708181 Comparator | Aug 2026 → Aug 2027 expected | gout | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07654231 Comparator | Jul 2026 → Dec 2027 expected | atherosclerotic cardiovascular disease, chronic kidney disease, diabetes mellitus, hyperlipidemia +2 | University of Texas Southwestern Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07247734 Comparator | Dec 2025 → Dec 2026 expected | type 1 diabetes mellitus | Asger Lund, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT04218786 Comparator | Dec 2025 → Mar 2026 | myocardial infarction, myocardial ischemia | Shifa Tameer-e-Millat University | Withdrawn | No outcome recorded |
| Phase 2 | NCT07145229 Comparator | Aug 2025 → May 2026 overdue | gout | Atom Therapeutics Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06768294 Comparator | Jan 2025 → Jun 2026 overdue | chondrocalcinosis | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06270225 Comparator | Mar → Oct 2024 | gout | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05949281 Comparator | Aug 2023 → Jan 2031 expected | cardiovascular disorder, type 1 diabetes mellitus | Asger Lund, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05936268 Comparator | Jul 2023 → Feb 2024 | gout | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05936281 Comparator | Jul 2023 → Jan 2024 | gout | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05503225 Comparator | Nov 2022 → Sep 2025 overdue | intracranial arteriosclerosis | Chinese University of Hong Kong | Recruiting | No outcome recorded |
| Phase 2 | NCT04857931 Comparator | Jun 2022 → Mar 2023 | heart failure | Montreal Heart Institute | Terminated | No outcome recorded |
| Phase 2 | NCT05726019 Comparator | Feb 2022 → Dec 2025 | Dressler syndrome, acute coronary syndrome, atrial fibrillation, coronary artery disorder +1 | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04867226 Comparator | May → Jun 2021 | COVID-19 | Hawler Medical University | Completed | No outcome recorded |
| Phase 2 | NCT04367168 Comparator | May 2020 → Apr 2021 | COVID-19 | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Terminated | No outcome recorded |
| Phase 2 | NCT04363437 Comparator | Apr → Jul 2020 | COVID-19 | Maimonides Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT04360980 Comparator | Mar 2020 → Jan 2021 | COVID-19 | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT04130204 Background | Feb 2020 → May 2021 | gout | Dyve Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03693781 Comparator | Apr 2019 → Apr 2022 | amyotrophic lateral sclerosis | University Hospital of Modena | Completed | No outcome recorded |
| Phase 2 | NCT03888846 Background | Mar → Aug 2019 | Behcet disease | Ipekyolu Ilac Ltd. Sti | Completed | No outcome recorded |
| Phase 2 | NCT04056039 Comparator | Aug 2018 → Jun 2019 | cardiovascular disorder, rheumatoid arthritis | Hospital Central "Dr. Ignacio Morones Prieto" | Completed | No outcome recorded |
| Phase 2 | NCT03376698 Comparator | Jun 2017 → Mar 2022 | coronary artery disorder, diarrheal disease, type 2 diabetes mellitus | University of the Ryukyus | Completed | No outcome recorded |
| Phase 2 | NCT02330796 Comparator | Apr → Nov 2015 | gout | Revive Therapeutics, Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02252835 Background | Aug → Dec 2014 | gout | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02128490 Background | May 2014 → Sep 2015 | gout | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT02063997 Comparator | Mar 2014 → Jan 2015 | gout | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01755949 Comparator | Mar 2013 → Dec 2016 | atrial fibrillation | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT01416402 Background | Aug → Oct 2011 | gout | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01399008 Background | Jun 2011 → Feb 2012 | gout | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01336686 Background | May → Nov 2011 | gout | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00840489 Comparator | Jan 2009 → Dec 2012 | chronic hepatitis C virus infection | Hospital Universitario Ramon y Cajal | Terminated | No outcome recorded |
| Phase 2 | NCT00723268 Comparator | May 2007 → Aug 2008 | mouth disorder | Mashhad University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT00700297 Comparator | Aug 2002 → Oct 2005 | Behcet disease | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT06217120 Comparator | Mar 2024 → Oct 2025 | coronary microvascular disorder, diastolic heart failure | Montreal Heart Institute | Unknown | No outcome recorded |
| Phase 2/3 | NCT04359095 Comparator | Aug 2020 → Mar 2021 | COVID-19 | National University of Colombia | Completed | No outcome recorded |
| Phase 2/3 | NCT03905759 Comparator | Apr 2019 → Apr 2020 | atrial fibrillation | doaa rashwan | Unknown | No outcome recorded |
| Phase 2/3 | NCT00754819 Comparator | Apr 2008 → Sep 2009 | acute coronary syndrome | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 325 trials | ||||||
| Phase 3 | NCT06763055 Comparator | Feb 2025 → Jan 2028 expected | intracerebral hemorrhage | The George Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT06998862 Comparator | Feb 2025 → Dec 2028 expected | chronic kidney disease | Hospital General Universitario Gregorio Marañon | Recruiting | No outcome recorded |
| Phase 3 | NCT05873881 Comparator | Jan 2024 → Jun 2027 expected | heart failure | Hamilton Health Sciences Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT05739929 Comparator | Mar 2023 → Aug 2024 | coronary artery disorder | Helwan University | Unknown | No outcome recorded |
| Phase 3 | NCT05737680 Comparator | Feb 2023 → Dec 2024 | idiopathic recurrent pericarditis | Hippocration General Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05162742 Comparator | Dec 2022 → Dec 2025 overdue | aortic valve calcification, aortic valve stenosis, calcinosis | Radboud University Medical Center | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05633810 Comparator | Dec 2022 → Dec 2027 expected | cardiovascular disorder, type 2 diabetes mellitus | Montreal Heart Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT05459974 Comparator | Jun 2022 → Nov 2023 | atrial fibrillation | Stony Brook University | Unknown | No outcome recorded |
| Phase 3 | NCT04774159 Comparator | May 2021 → Dec 2029 expected | atherosclerosis, peripheral arterial disease | Population Health Research Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT04539873 Comparator | Apr → Oct 2021 | COVID-19 | Fundación Universitaria de Ciencias de la Salud | Terminated | No outcome recorded |
| Phase 3 | NCT04516941 Comparator | Jan 2021 → Aug 2022 | COVID-19 | Insel Gruppe AG, University Hospital Bern | Terminated | No outcome recorded |
| Phase 3 | NCT04997551 Comparator | Sep 2020 → Sep 2021 | COVID-19 | Biogipuzkoa Health Research Institute | Unknown | No outcome recorded |
| Phase 3 | NCT04328480 Comparator | Apr 2020 → Apr 2021 | COVID-19 | Estudios Clínicos Latino América | Completed | No outcome recorded |
| Phase 3 | NCT04322682 Comparator | Mar 2020 → Jan 2021 | COVID-19 | Montreal Heart Institute | Terminated | No outcome recorded |
| Phase 3 | NCT04381936 Comparator | Mar 2020 → Sep 2028 expected | pneumonia | University of Oxford | Recruiting | No outcome recorded |
| Phase 3 | NCT03128905 Comparator | Feb 2018 → May 2022 | chondrocalcinosis | Lille Catholic University | Completed | No outcome recorded |
| Phase 3 | NCT03048825 Comparator | Feb 2018 → Aug 2024 | ST-elevation myocardial infarction | Population Health Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT03015831 Comparator | Oct 2017 → Apr 2019 | atrial fibrillation, colchicine poisoning | Jordan Collaborating Cardiology Group | Terminated | No outcome recorded |
| Phase 3 | NCT02898610 Comparator | Dec 2016 → Jan 2024 | transient ischemic attack | University College Dublin | Completed | No outcome recorded |
| Phase 3 | NCT02551094 Comparator | Dec 2015 → Jul 2019 | coronary artery disorder, myocardial infarction | Montreal Heart Institute | Completed | No outcome recorded |
| Phase 3 | NCT02139046 Background | Apr 2014 → Nov 2015 | gout | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT03021343 Comparator | Oct 2012 → Jan 2015 | cardiac rhythm disease | Jordan Collaborating Cardiology Group | Completed | No outcome recorded |
| Phase 3 | NCT01552187 Comparator | Mar 2012 → Jun 2014 | atrial fibrillation, pericardial effusion | Maria Vittoria Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00370760 Comparator | Sep 2006 → ? | proliferative vitreoretinopathy | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT00128453 Comparator | Aug 2005 → Jun 2012 | pericarditis | Azienda Sanitaria Locale 3, Torino | Completed | No outcome recorded |
| Phase 420 trials | ||||||
| Phase 4 | NCT07661030 Background | Jul 2026 → Jul 2027 expected | gout | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06396858 Comparator | Jul 2026 → Aug 2027 expected | ischemic stroke | Brazilian Clinical Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04875702 Comparator | Feb 2024 → Sep 2028 expected | gout | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05850091 Comparator | Dec 2023 → Jun 2027 expected | coronary artery disorder | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06078904 Comparator | Oct → Dec 2023 | coronary artery disorder | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Completed | No outcome recorded |
| Phase 4 | NCT05618353 Comparator | Aug 2023 → Jul 2028 expected | coronary artery disorder | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 4 | NCT06342609 Comparator | Mar 2023 → Sep 2024 | coronary atherosclerosis | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT05698680 Comparator | Jan 2023 → Feb 2026 | gout | University Medicine Greifswald | Terminated | No outcome recorded |
| Phase 4 | NCT05200052 Comparator | Feb → Aug 2022 | myocardial infarction | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT05246072 Comparator | Nov 2021 → Feb 2022 | COVID-19 | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT04323280 Comparator | Feb 2020 → Jul 2023 | pericarditis | Rabin Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT05168137 Comparator | Feb 2020 → Jun 2022 | HIV infectious disease, colchicine poisoning | Mahidol University | Unknown | No outcome recorded |
| Phase 4 | NCT03226899 Comparator | Jul 2017 → Feb 2019 | chronic kidney disease, gout | Ironwood Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT02500641 Background | Aug 2015 → May 2017 | gout | Menarini International Operations Luxembourg SA | Completed | No outcome recorded |
| Phase 4 | NCT01994226 Comparator | Jan 2014 → Mar 2016 | gout | Keele University | Completed | No outcome recorded |
| Phase 4 | NCT01906749 Comparator | Jun 2013 → Jun 2016 | acute coronary syndrome | Maria Vittoria Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02594111 Comparator | May 2013 → Aug 2019 | acute coronary syndrome, coronary artery disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT01451645 Comparator | Oct 2011 → Aug 2012 | gout | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01112982 Background | May 2010 → Dec 2014 | gout | University of South Florida | Completed | No outcome recorded |
| Phase 4 | NCT00179413 Comparator | Jan 2000 → Dec 2009 | cirrhosis of liver, fibrotic liver disease, hepatitis C virus infection | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase not applicable12 trials | ||||||
| — | NCT07476625 Comparator | Apr 2026 → Mar 2027 expected | PFAPA syndrome | Wenjie Zheng | Not yet recruiting | No outcome recorded |
| — | NCT07074990 Comparator | Nov 2023 → Aug 2024 | infectious disease with sepsis | Tanta University | Completed | No outcome recorded |
| — | NCT04073797 Comparator | Mar 2023 → Oct 2025 overdue | atherosclerosis, familial hypercholesterolemia | University of Cambridge | Recruiting | No outcome recorded |
| — | NCT05930002 Comparator | Jul 2021 → Sep 2022 | COVID-19 | Ain Shams University | Completed | No outcome recorded |
| — | NCT05911022 Comparator | Jul 2021 → Aug 2022 | COVID-19 | Ain Shams University | Completed | No outcome recorded |
| — | NCT04697602 Comparator | Jan 2021 → Aug 2023 | gout | National Taiwan University Hospital | Terminated | No outcome recorded |
| — | NCT04527562 Comparator | Jul → Nov 2020 | COVID-19 | Dhaka Medical College | Completed | No outcome recorded |
| — | NCT04155879 Comparator | Nov 2019 → Nov 2022 | atrial fibrillation | Hillel Yaffe Medical Center | Unknown | No outcome recorded |
| — | NCT03735134 Comparator | Nov 2018 → Jul 2020 | myocardial infarction | Hillel Yaffe Medical Center | Unknown | No outcome recorded |
| — | NCT03659058 Comparator | Mar 2016 → Aug 2018 | fibrotic liver disease | Zagazig University | Completed | No outcome recorded |
| — | NCT02035891 Comparator | Dec 2013 → Sep 2019 | diabetic kidney disease | Chongqing Medical University | Unknown | No outcome recorded |
| — | NCT00983177 Comparator | Mar 2010 → Oct 2011 | calcific tendinitis | Bnai Zion Medical Center | Unknown | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-01-13 | Takeda | Takeda Update Regarding Colcrys Litigation takeda.com ↗ |
| 2015-01-13 | Takeda | Prasco and Takeda Enter into Agreement to Market Authorized Generic of Colcrys ® (colchicine, USP) in the United States takeda.com ↗ |
Evidence & citations 29 cited values
Every value below carries the sentence it was read from. 281 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Colchicine | “colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19” NCT01601132 ↗277“Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19” NCT04997551 ↗ “remdesivir (Veklury), Colchicine, anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab, Casirivimab \& Imdevimab.” NCT04790240 ↗ “Dexamethasone 20MG once daily for 4 days with additional colchicine therapy for 3 months” NCT04323280 ↗ “Colchicine tablet 0.5 mg once-daily for two weeks, then twice daily for two weeks” NCT07247734 ↗ “Colchicine0.5 mg Oral Tablet” NCT05324423 ↗ “Drug: Colchicine” NCT04056039 ↗ |
| Known as | (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol\[a\]heptalen-7-yl) acetamide | “The chemical name for colchicine is (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol\[a\]heptalen-7-yl) acetamide.” NCT05890664 ↗ |
| Known as | COLC | “This prospective, single-arm pharmacodynamic study assessed the effect of colchicine (COLC) [Strides Pharma UK Ltd, Watford, Hertfordshire, England] 0.5 mg administered orally...” PMID 39826082 ↗ Jan 2025 |
| Known as | Colchcine | ChEMBL registry synonym — accepted as the source's own label CHEMBL107 ↗ |
| Known as | COLCHICINA LIRCA | “Colchicine 1 mg day (COLCHICINA LIRCA ® ACARPIA Farmaceutici S.r.l.)” NCT04224545 ↗ |
| Known as | Colchicine component of col-probenecid | ChEMBL registry synonym — accepted as the source's own label CHEMBL107 ↗ |
| Known as | Colchicine component of colbenemid | ChEMBL registry synonym — accepted as the source's own label CHEMBL107 ↗ |
| Known as | Colchicine component of mitigare | ChEMBL registry synonym — accepted as the source's own label CHEMBL107 ↗ |
| Known as | Colchicine component of proben-c | ChEMBL registry synonym — accepted as the source's own label CHEMBL107 ↗ |
| Known as | Colchicine Pill | “Drug: Colchicine Pill” NCT06855433 ↗ |
| Known as | Colchicine Tablets | “Colchicine Tablets (Each tablet contains colchicine 0.5mg)” NCT05038449 ↗ |
| Known as | Colchicine Tablets 0.5mg | “Colchicine 0.5 mg oral tablet (Colchicine Tablets 0.5mg, Synmosa)” NCT07536373 ↗ |
| Known as | Colchicinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL107 ↗ |
| Known as | Colchimax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02363725 ↗ |
| Known as | Colchineos | ChEMBL registry synonym — accepted as the source's own label CHEMBL107 ↗ |
| Known as | Colchisol | ChEMBL registry synonym — accepted as the source's own label CHEMBL107 ↗ |
| Known as | Colcrys | “Colchicine (Colcrys®)” NCT01451645 ↗ |
| Known as | Colcrys TM, Colchicine 0.6 mg | “Colcrys TM, Colchicine 0.6 mg” NCT00506883 ↗ |
| Known as | generic colchicine tablets (SIN 12490P) | “generic colchicine tablets (SIN 12490P)” NCT02176460 ↗ |
| Known as | Gloperba | ChEMBL registry synonym — accepted as the source's own label CHEMBL107 ↗ |
| Known as | LoDoCo | “LODOCO is low-dose colchicine at 0.5mg daily, ii is an FDA approved anti-inflammatory drug, to prevent cardiovascular events in patients with coronary artery disease.” NCT06874192 ↗1“Intervention group will receive LoDoCo (Colchicine 0.5mg), oral, once daily.” NCT07654231 ↗ |
| Known as | Mitigare | ChEMBL registry synonym — accepted as the source's own label CHEMBL107 ↗ |
| Known as | NSC-757 | ChEMBL registry synonym — accepted as the source's own label CHEMBL107 ↗ |
| Known as | opocalcium | “Patients assigned to this group will receive the Colchicine opocalcium 1mg treatment.” NCT03128905 ↗ |
| Known as | Tiofarma | “The intervention tablets are commercially available Colchicine "Tiofarma"” NCT04601883 ↗ |
| Action | Inhibit | “Colchicine is a supressor of hepatic CYP1A2” NCT00983905 ↗ |
| Modality | Small molecule | “Colchicine is an alkaloid compound” NCT03933007 ↗ |
| Route | Oral | “Patients receive colchicine orally twice daily for 24 months.” NCT00004368 ↗ |
| Target | CYP1A2 | “Colchicine is a supressor of hepatic CYP1A2” NCT00983905 ↗ |